Psilocybin’s lasting action requires pyramidal cell types and 5-HT2A receptors
This mouse study investigates how psilocybin affects different types of brain cells in the medial frontal cortex (mPFC; decision-making processes and judgement). The research finds that psilocybin increases dendritic spine density in both pyramidal tract (PT) and intratelencephalic (IT) neurons, but only PT neurons are essential for psilocybin's anti-stress effects through 5-HT2A receptor activation.
Abstract
Psilocybin is a serotonergic psychedelic with therapeutic potential for treating mental illnesses. At the cellular level, psychedelics induce structural neural plasticity, exemplified by the drug-evoked growth and remodelling of dendritic spines in cortical pyramidal cells. A key question is how these cellular modifications map onto cell-type-specific circuits to produce the psychedelics’ behavioural actions. Here we use in vivo optical imaging, chemogenetic perturbation and cell-type-specific electrophysiology to investigate the impact of psilocybin on the two main types of pyramidal cells in the mouse medial frontal cortex. We find that a single dose of psilocybin increases the density of dendritic spines in both the subcortical-projecting, pyramidal tract (PT) and intratelencephalic (IT) cell types. Behaviourally, silencing the PT neurons eliminates psilocybin’s ability to ameliorate stress-related phenotypes, whereas silencing IT neurons has no detectable effect. In PT neurons only, psilocybin boosts synaptic calcium transients and elevates firing rates acutely after administration. Targeted knockout of 5-HT2A receptors abolishes psilocybin’s effects on stress-related behaviour and structural plasticity. Collectively, these results identify that a pyramidal cell type and the 5-HT2A receptor in the medial frontal cortex have essential roles in psilocybin’s long-term drug action
Research Summary of 'Psilocybin’s lasting action requires pyramidal cell types and 5-HT2A receptors'
Introduction
Psilocybin is a serotonergic psychedelic that produces sustained improvement in depressive symptoms in clinical trials and has been shown in rodents to provoke enduring increases in dendritic spine density and size in cortical pyramidal cells. Neocortical pyramidal neurons are heterogeneous, principally comprising pyramidal tract (PT) neurons that project to subcortical targets and intratelencephalic (IT) neurons that project within the forebrain; these cell types differ in physiology and circuit participation. Prior work demonstrated psychedelic-evoked structural plasticity in pyramidal cells, but it remained unclear which excitatory cell types drive the drugs’ behavioural effects and how receptor mechanisms such as 5-HT2A contribute at the cell-type level. Shao and colleagues set out to determine how a single dose of psilocybin affects PT and IT neurons in the mouse medial frontal cortex, and whether those effects are necessary for psilocybin’s longer-term action on stress-related behaviours. The study combined longitudinal in vivo two-photon structural imaging, awake dendritic calcium imaging, cell type–specific electrophysiology, chemogenetic silencing, and conditional, regionally targeted knockout of the Htr2a gene (encoding 5-HT2A) to map structural, physiological and behavioural consequences to cell types and receptor expression.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Full Text PDF
Full Paper PDF
Pro members can view the original manuscript directly in the browser.
Study Details
- Study Typeindividual
- Journal
- Compound
- Topic
- Author
- APA Citation
Shao, L., Liao, C., Davoudian, P. A., Savalia, N. K., Jiang, Q., Wojtasiewicz, C., Tan, D., Nothnagel, J. D., Liu, R., Woodburn, S. C., Bilash, O. M., Kim, H., Che, A., & Kwan, A. C. (2025). Psilocybin’s lasting action requires pyramidal cell types and 5-HT2A receptors. Nature, 642(8067), 411-420. https://doi.org/10.1038/s41586-025-08813-6
References (16)
Papers cited by this study that are also in Blossom
Goodwin, G. M., Aaronson, S. T., Alvarez, O. et al. · New England Journal of Medicine (2022)
Davis, A. K., Barrett, F. S., May, D. G. et al. · JAMA Psychiatry (2021)
Carhart-Harris, R. L., Giribaldi, B., Watts, R. et al. · New England Journal of Medicine (2021)
Bogenschutz, M. P., Ross, S., Bhatt, S. R. et al. · JAMA Psychiatry (2022)
Ly, C., Greb, A. C., Cameron, L. P. et al. · Cell Reports (2018)
Shao, L-X,, Liao, C., Gregg, I. et al. · Neuron (2021)
De La, M., Revenga, F., Zhu, B. et al. · Cell Reports (2021)
Kwan, A. C., Olson, D. E., Preller, K. H. et al. · Nature Medicine (2022)
Cameron, L. P., Tombari, R. J., Lu, J. et al. · Nature (2020)
Lu, J., Tjia, M., Mullen, B. et al. · Molecular Psychiatry (2021)
Show all 16 referencesShow fewer
Savalia, N., Shao, L-X,, Kwan, A. C. · Trends in Neuroscience (2021)
Halberstadt, A. L., Chatha, M., Klein, A. K. et al. · Neuropharmacology (2020)
Cameron, L. P., Patel, S. D., Vargas, M. V. et al. · ACS Chemical Neuroscience (2023)
Hesselgrave, N., Troppoli, T. A., Wulff, A. B. et al. · PNAS (2021)
Kaplan, A. L., Confair, D. N., Kim, K. et al. · Nature (2022)
Cao, D., Yu, J., Wang, H. et al. · Science (2022)
Cited By (4)
Papers in Blossom that reference this study
Garcia-Romeu, A., Naudé, G. P., Rebman, A. W. et al. · Scientific Reports (2026)
Ellis, S., Bostian, C., Donnelly, A. et al. · Journal of Affective Disorders (2025)
Agrawal, R., Gillie, D., Mungenast, A. et al. · ACS Chemical Neuroscience (2025)
Jain, M. K., Gumpper, R. H., Slocum, S. T. et al. · Neuron (2025)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.